Catheter-related thrombosis in central venous catheter coated with or without chlorhexidine - a randomised controlled trial

Catheter-related thrombosis in central venous catheter coated with or without chlorhexidine - a randomised controlled trial - CVC-Coating

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00035159

Enrollment

120

Registered

2024-12-02

Start date

2025-10-01

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embolism and thrombosis of the internal jugular vein I82.8

Interventions

Group 1: Randomised controlled study to investigate catheter-related thrombi on central venous catheters in patients with tumours in the upper abdomen (liver, pancreas, stomach, oesophagus) who requir

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Tumour disease inpancreas, liver, oesophagus, stomach or duodenum. - Elective surgery to remove these tumours, e.g. liver resection, pylorus-preserving pancreatic head resection or gastrectomy. - Indication for placement of a CVC. - Placement of CVC in right internal jugular vein has to be possible.

Exclusion criteria

Exclusion criteria: - Refusal to participate in the study. - Unable to give consent. - Non-elective surgery. - Known thrombus in the right internal jugular vein or superior vena cava. - Known coagulation disorder. - Known allergy to chlorhexidine.

Design outcomes

Primary

Measure	Time frame
The central venous catheters are examined sonographically daily starting after the operation (day 0) until removal or max. 14 days after the operation. The time of the first detectable thrombus is recorded as the primary endpoint.	—

Secondary

Measure	Time frame
At the end of the observation period, the dependence of thrombus formation and differences in relation to the following factors are analysed: - type of thrombus (fibrin sheat/fibrin sleeve, mural thrombosis, venous thrombus, intraluminal thrombus). - number of closed lumen. - max. diameter of the thrombus. - max. length of the thrombus. - growing of the thrombus. - Laboratory measurements: inflammation- and thrombosismarker (white blood cells, c-related peptide, procalcitonin, platelets, d-dimers, fibrinogen). - heart rhythm: regular, irregular. - type of tumor. - type of surgery. - age. - BMI. - ASA-classification. - drugs for anticoagulation. - thrombosis in history. - nicotinabusus. - pre-existing conditions: Diabetes mellitus, arterial hypertension, hyperlipidaemia/-cholesterolaemia. - ports/pace makers etc. in jugular/subclavian vein or Vena cava superior.	—

Measure

Time frame

At the end of the observation period, the dependence of thrombus formation and differences in relation to the following factors are analysed: - type of thrombus (fibrin sheat/fibrin sleeve, mural thrombosis, venous thrombus, intraluminal thrombus). - number of closed lumen. - max. diameter of the thrombus. - max. length of the thrombus. - growing of the thrombus. - Laboratory measurements: inflammation- and thrombosismarker (white blood cells, c-related peptide, procalcitonin, platelets, d-dimers, fibrinogen). - heart rhythm: regular, irregular. - type of tumor. - type of surgery. - age. - BMI. - ASA-classification. - drugs for anticoagulation. - thrombosis in history. - nicotinabusus. - pre-existing conditions: Diabetes mellitus, arterial hypertension, hyperlipidaemia/-cholesterolaemia. - ports/pace makers etc. in jugular/subclavian vein or Vena cava superior.

—

Countries

Germany

Contacts

Public ContactSebastian Gibb

Klinik für Anästhesie, Intensiv-, Notfall- und Schmerzmedizin, Universitätsmedizin Greifswald

sebastian.gibb@med.uni-greifswald.de+493834865801

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026